1cP-LSD is a synthetic lysergamide that functions as a prodrug to LSD-25, meaning it converts into active LSD after entering the body. It was first introduced as a legal alternative to LSD in regions where LSD-25 is classified as a controlled substance. Known for mimicking the effects of traditional LSD while offering slightly softer visuals and a more manageable experience for some, 1cP-LSD has quickly become a popular choice in the psychedelic research and exploration community.

• Prodrug to LSD
  Once ingested, 1cP-LSD undergoes hydrolysis, removing the cyclopropionyl group and converting into LSD-25 in the liver. This process is similar to how 1P-LSD functions, making 1cP-LSD pharmacologically active as LSD.

• Chemically stable variant
  The addition of the cyclopropionyl group not only makes it legal in some jurisdictions but also improves shelf stability, extending the compound’s viability over time compared to LSD in freebase form.

• Visual and cognitive effects
  Users report classic psychedelic visuals such as fractal patterns, enhanced colors, and perceptual shifts, along with elevated mood, introspection, and a sense of connection to surroundings or ideas.

• Preferred for research
  Due to its structural similarity to LSD-25 and often more favorable legal status, 1cP-LSD is widely used in chemical, pharmacological, and behavioral studies as a proxy for LSD.

• Milder subjective profile
  Some individuals find 1cP-LSD to produce a smoother, less overwhelming trip than traditional LSD, making it more approachable for sensitive or first-time users.

• Available in multiple forms
  It is most commonly sold on blotter paper dosed in micrograms or in powder form for advanced research applications.

The legal status of 1cP-LSD varies depending on local drug laws and regulatory frameworks. Although it has not been scheduled in many countries, its structural similarity to LSD-25 has led some governments to implement analog laws that may include it by extension. Before purchasing or possessing 1cP-LSD, it is crucial to review the legal standing in your specific country or region.

• Unscheduled in parts of Europe
  As of now, several EU countries (e.g., Germany before 2022, Netherlands) allowed 1cP-LSD as a legal research chemical. However, laws change frequently, so always check the latest updates.

• Banned in select countries
  Nations such as the UK and Sweden have explicitly banned 1cP-LSD under psychoactive substances legislation or analog scheduling acts.

• Legal gray area
  In some jurisdictions, 1cP-LSD is neither scheduled nor regulated, making it technically legal to possess, although not officially approved for consumption or sale.

• Controlled by analog laws
  The United States, Canada, and Australia have analog acts or federal analog laws that may apply to 1cP-LSD, potentially making it prosecutable if deemed similar to LSD in structure and effect.

• Sold for research purposes
  To stay compliant with most regulatory requirements, vendors (including us) sell 1cP-LSD strictly for research, chemical analysis, or educational use only—not for human consumption.

• Buyer responsibility
  Customers must ensure their local laws permit import or possession. Psycho Plug ships at the buyer’s risk if their region enforces stricter analog rules.

The effects of 1cP-LSD generally last between 8 to 12 hours, depending on dosage, individual metabolism, and method of ingestion. The timeline and intensity of the experience closely resemble that of LSD-25, with a gradual onset, defined peak, and smooth comedown.

• Onset within 30–90 minutes
  After ingestion, effects typically begin to appear in 30 to 90 minutes. This slow onset allows users to ease into the trip compared to faster-acting substances.

• Peak effects last 4–6 hours
  The most intense sensory and cognitive alterations tend to occur during this phase. Visuals become vivid, thoughts accelerate, and emotional responses intensify.

• Total duration is 8–12 hours
  From ingestion to return to baseline, the full arc of a 1cP-LSD experience spans several hours, demanding preparation and a safe setting.

• After-effects linger 1–2 hours
  After the peak, users often report a gentle “afterglow” phase with residual stimulation, slight visuals, or emotional clarity.

• Extended trips possible with higher doses
  High or repeated dosing can prolong the experience, sometimes pushing the timeline beyond 12 hours, especially if tolerance is low.

• No abrupt comedown
  Unlike stimulants or dissociatives, 1cP-LSD’s effects diminish gradually, reducing the chances of a hard landing or crash.

Dosing with 1cP-LSD typically follows the same microgram-based scale used for LSD-25, but users often report that its subjective potency can be slightly lower, requiring moderate adjustments for experienced psychonauts. The most common method of delivery is blotter paper infused with a precise microgram dose.

• Standard research dose: 100mcg
  This is the benchmark for a full psychedelic experience, producing strong visuals, altered perception, and introspective thought without overwhelming intensity.

• Light dose: 50–75mcg
  Ideal for beginners or those seeking a milder experience, this range delivers mild to moderate effects while minimizing emotional intensity.

• Common dose range: 100–125mcg
  Most experienced users find their comfort zone within this window, balancing visuals, cognition, and functionality.

• High dose: 150mcg or more
  At this level, the intensity rises sharply, increasing the risk of ego dissolution, confusion, and overwhelming sensory input. Reserved for highly experienced individuals.

• Microdose: 5–20mcg
  At this threshold, effects are sub-perceptual but may promote creativity, focus, and mood enhancement.

• Form-dependent accuracy
  Blotters are pre-measured and more convenient for controlled doses. Powder requires precision scales and handling, suitable for experienced researchers.

Proper storage is critical to maintaining the stability and potency of 1cP-LSD, especially over extended periods. Environmental exposure to light, heat, air, or moisture can degrade the compound, reducing its effectiveness and altering its chemical composition.

• Cool, dark, dry environment
  Store in a location that avoids sunlight, humidity, and high temperatures. A drawer, sealed container, or closet is suitable for short-term use.

• Ideal temperature: 20–25°C (68–77°F)
  Room temperature is acceptable, but avoid placing the product near heat sources or inside vehicles.

• Airtight storage containers
  Use vacuum-sealed foil, mylar bags, or amber glass vials to block light and limit oxygen exposure.

• Use desiccants when storing powder
  Including silica gel packs in the storage container helps absorb excess moisture and extends product life.

• Refrigeration for long-term storage
  For extended shelf life (6+ months), refrigeration is recommended. Ensure the container is sealed tightly to prevent condensation.

• Freezing is safe if sealed properly
  Deep freezing can preserve blotters or powder for over a year. Wrap blotters in foil and seal in a moisture-proof bag before freezing.

1cP-LSD is often considered a suitable entry point into the world of classical psychedelics due to its manageable intensity and consistent effects. While no psychedelic is entirely without risk, 1cP-LSD’s subjective profile makes it more forgiving than many alternatives, especially when used responsibly in a controlled setting.

• Mild-to-moderate intensity
  Compared to LSD-25, 1cP-LSD tends to produce smoother cognitive and visual transitions, making it less jarring for new users.

• More predictable than mushrooms
  Unlike psilocybin mushrooms, which vary in potency by species and batch, 1cP-LSD offers precise dosing via standardized blotters.

• Lower incidence of mental overload
  At low to moderate doses, users report less likelihood of overwhelming thought loops or anxiety spirals, which are common concerns among beginners.

• Gradual onset provides adjustment time
  With a slower onset of 30–90 minutes, users have time to prepare emotionally and physically for the experience.

• Long duration requires preparation
  The 8–12 hour effect window means beginners need to plan their setting, responsibilities, and recovery time carefully.

• Mental health history matters
  Individuals with a history of psychosis, bipolar disorder, or extreme anxiety should avoid use without clinical supervision.

• Safe set and setting is critical
  Even a manageable psychedelic like 1cP-LSD can turn difficult if used in a chaotic or unsupportive environment. Preparation is vital.

Microdosing involves taking very small, sub-perceptual amounts of a psychedelic compound—typically between 5 and 20 micrograms. Many users turn to 1cP-LSD as an alternative to LSD-25 for microdosing, especially in regions where 1cP-LSD is not scheduled. While scientific research is still limited, anecdotal reports support its efficacy for mental clarity, mood balance, and creative enhancement.

• Sub-perceptual effects
  Properly dosed, 1cP-LSD microdoses do not induce hallucinations or significant alterations in perception, allowing users to function normally throughout the day.

• Common microdose: 6–15mcg
  This is typically one-tenth of a full 100mcg blotter. Some users cut a standard blotter into 10 equal parts, though volumetric dosing is more precise.

• Potential benefits
  Users report increased mental clarity, reduced social anxiety, improved mood, enhanced focus, and even better sleep cycles over time.

• Protocols available
  The most common regimens include the Fadiman protocol (1 day on, 2 days off) or the Stamets stack, which combines microdosing with Lion’s Mane and niacin.

• Tolerance buildup is minimal
  At microdose levels, tolerance develops much slower than with full doses, making it feasible to follow weekly schedules without diminishing effects.

• Still unregulated in many places
  Despite its popularity, microdosing remains legally ambiguous in many jurisdictions. Possession—even of micro amounts—can carry legal risks.

• Measurement accuracy matters
  Volumetric dosing (dissolving blotter in distilled water or alcohol for precision measurement) is the most reliable way to microdose safely and consistently.

Most standard drug screening panels do not test for 1cP-LSD or LSD-like compounds. However, the potential for detection depends on the type of test used and whether it’s designed to look for lysergamide metabolites. While casual use typically goes unnoticed in employment or legal drug tests, specialized testing environments may reveal its presence.

• Not included in standard 5-panel or 10-panel tests
  These common tests used by employers or parole officers typically target substances like THC, cocaine, opioids, amphetamines, and benzodiazepines—not psychedelics.

• Advanced LSD-specific tests may detect metabolites
  After metabolizing into LSD-25, traces may show up in tests specifically calibrated to detect lysergic acid derivatives.

• Detection window is short
  LSD and its analogs are typically cleared from the body within 24 to 48 hours, especially at standard doses.

• Urine and hair testing sensitivity
  Specialized urine tests can sometimes detect LSD metabolites at microgram levels. Hair testing can show use within the past 90 days but is rarely used for psychedelics.

• Low priority in workplace screening
  Most employers do not test for psychedelics due to the high cost and rarity of use compared to stimulants or depressants.

• False positives are uncommon
  1cP-LSD does not tend to trigger false positives for other substances, reducing the risk of accidental detection.

1cP-LSD produces a spectrum of sensory, emotional, and cognitive effects that are strikingly similar to those of LSD-25. These effects can vary by dose, environment, and user sensitivity but typically include perceptual changes, heightened emotional states, and enhanced mental clarity.

• Visual enhancements
  Users commonly report brightened colors, geometric patterns, trailing lights, and movement in stationary objects—especially during the peak.

• Altered time perception
  Time may feel slowed, sped up, or looped. Moments can seem stretched, which often leads to profound introspective insights or emotional release.

• Increased introspection
  Deep thought, inner dialogue, and philosophical awareness often emerge. Many users explore unresolved personal issues or gain new perspectives on life.

• Emotional amplification
  Emotions are intensified—joy can feel euphoric, while anxiety may be amplified without proper mindset or setting.

• Enhanced sensory sensitivity
  Sounds may seem clearer or layered; touch becomes heightened; smells are more pronounced. Music, in particular, is often deeply moving.

• Visual closed-eye imagery
  When eyes are closed, users frequently experience vivid visuals like kaleidoscopic patterns, symbolic imagery, or moving scenery.

• Connectedness and ego dissolution
  At higher doses, users may lose sense of self (ego death) or feel deeply connected to nature, others, or abstract concepts.

Although 1cP-LSD has not been formally approved for medical use, its close relationship to LSD-25 has sparked significant interest in its potential therapeutic benefits. While clinical trials on 1cP-LSD specifically are lacking, early studies on LSD and anecdotal reports suggest a range of psychological applications that merit further exploration.

• Similar mechanism to LSD
  1cP-LSD acts as a prodrug to LSD-25, which binds primarily to serotonin 5-HT2A receptors—implicated in mood, cognition, and sensory processing.

• Potential for treating depression and anxiety
  LSD has shown promise in studies as a treatment for treatment-resistant depression and generalized anxiety disorder. 1cP-LSD may offer similar outcomes when used responsibly.

• Applications in addiction therapy
  Early LSD research and anecdotal microdosing reports indicate possible benefits in addressing alcohol and tobacco addiction through behavioral reset mechanisms.

• Facilitator of emotional processing
  Many users describe breakthroughs in unresolved trauma, grief, or internal conflict during sessions, which mirror therapeutic goals in psychedelic-assisted therapy.

• Improved creative cognition
  Enhanced pattern recognition, divergent thinking, and problem-solving capacities have been reported by both microdosers and full-dose users.

• Not FDA or EMA approved
  Despite its potential, 1cP-LSD remains unregulated as a therapeutic agent, and clinical administration is currently prohibited in most countries.

• Requires supervised setting for safe therapeutic use
  Any serious attempt to use psychedelics for healing should be conducted in a supervised environment with trained guides or therapists.

1cP-LSD is known for its smooth transition out of the psychedelic state, and many users describe a “gentle comedown” or even a pleasant “afterglow.” Unlike stimulants or harsher psychedelics, 1cP-LSD typically leaves users with a sense of peace, emotional clarity, or mental stillness after the peak effects wear off.

• Smooth return to baseline
  The shift back to normal consciousness occurs gradually, reducing the risk of mental fatigue or emotional crash that some users experience with shorter-acting compounds.

• Lingering emotional uplift
  Users often report feeling emotionally lighter or more inspired for hours or even days after the trip ends, especially after introspective sessions.

• Residual visual activity
  Minor visual trails or distortions may persist for 1–2 hours after peak effects but generally diminish without discomfort.

• Low rebound anxiety
  Unlike substances like MDMA or high-dose THC, 1cP-LSD rarely causes anxiety, agitation, or depressive moods once the experience is over.

• Mental clarity and focus
  Some report increased cognitive clarity and improved organization of thoughts during the afterglow, especially when the trip is taken in a calm, intentional setting.

• Increased openness and empathy
  Enhanced interpersonal connection, insight into personal relationships, and compassion for others often emerge during the tail-end of the trip and beyond.

While 1cP-LSD is generally well-tolerated when used responsibly, it still carries several psychological and legal risks. Like all psychedelics, its effects are powerful and can be destabilizing if not approached with care. Physical toxicity appears to be low, but mental preparation is essential to avoid adverse outcomes.

• Psychological distress
  High doses or improper settings can trigger anxiety, paranoia, panic attacks, or dissociative episodes. This is especially risky for users with underlying mental health conditions.

• Long trip duration
  The 8–12 hour timeline can become overwhelming if the user is unprepared or trapped in a setting they can’t change mid-experience.

• Hallucinogen Persisting Perception Disorder (HPPD)
  Although rare, repeated use of lysergamides may lead to persistent visual disturbances or “tracers” long after the drug has worn off.

• Emotional vulnerability
  Deep introspection can unearth traumatic memories or unresolved issues, leading to intense emotional release or discomfort.

• Not approved for human consumption
  1cP-LSD is a research chemical and lacks clinical approval, meaning there are no formal safety guidelines or standardized medical data.

• Legality complications
  Depending on jurisdiction, possession or use may be punishable under analog or controlled substance laws.

• Risk of mislabeling or impurities from unreliable sources
  Low-quality vendors may sell mislabeled blotters or contaminated substances, increasing the chance of unintentional exposure to harmful chemicals.

Yes, as with all serotonergic psychedelics, tolerance to 1cP-LSD develops quickly after use. This means repeated dosing over a short period will lead to reduced effectiveness and weaker effects. Understanding tolerance is crucial for safe and intentional psychedelic exploration.

• Rapid tolerance buildup
  Tolerance begins developing after just one use and can reduce the effects of subsequent doses taken within 24–72 hours.

• Cross-tolerance with LSD and similar lysergamides
  1cP-LSD shares a tolerance profile with LSD-25, AL-LAD, 1P-LSD, and other serotonin-affecting psychedelics, meaning repeated use of any of them will affect response to others.

• Wait 7–14 days between sessions
  To allow serotonin receptor levels to reset, most experienced users recommend at least a week of spacing between full doses.

• Microdosing still causes cumulative tolerance
  Even sub-perceptual doses can slowly build tolerance if taken too frequently. Break periods are essential in any microdosing protocol.

• No long-term tolerance accumulation
  Unlike addictive substances, psychedelics do not build permanent tolerance. After sufficient time off, sensitivity returns to baseline.

• Re-dosing in one session has minimal benefit
  Attempting to increase effects mid-trip often fails due to rapidly established acute tolerance.

1cP-LSD is often described as slightly less potent than LSD-25 on a microgram-for-microgram basis, but the differences are subtle and subjective. Once metabolized, 1cP-LSD converts into LSD-25 in the body, meaning its final effect profile is nearly identical. However, differences in onset, peak dynamics, and overall “smoothness” have been reported by users.

• Lower perceived intensity per microgram
  Some users find that 100mcg of 1cP-LSD feels slightly less intense than an equivalent dose of pure LSD-25, especially in visual complexity.

• More gradual onset
  1cP-LSD may take longer to come on, which can reduce the shock factor or anxiety sometimes associated with LSD’s abrupt initial effects.

• Similar duration and visuals
  The trip length and visual intensity are nearly the same, especially once the active LSD is present in the bloodstream.

• Easier headspace for some users
  Many report a less intense psychological or emotional impact, allowing for a more functional or contemplative trip.

• No difference in serotonin receptor binding
  Once metabolized, both compounds bind to the same 5-HT2A receptors, explaining the nearly indistinguishable core effects.

• Effect variability influenced by metabolism
  The conversion rate from 1cP-LSD to LSD-25 can vary slightly by individual, which may explain reports of differing potency.

While both 1cP-LSD and 1P-LSD are LSD prodrugs and produce nearly identical effects once metabolized, they differ slightly in chemical structure and possibly in subjective experience. These distinctions are of interest primarily to chemists and experienced psychonauts, as the differences in effects are often nuanced.

• Structural difference
  1cP-LSD contains a cyclopropionyl group, while 1P-LSD contains a propionyl group. Both groups detach during metabolism to form LSD-25.

• Rate of onset may vary
  Some users report that 1P-LSD kicks in slightly faster than 1cP-LSD, though this is anecdotal and varies by metabolism.

• Subjective differences in clarity
  1cP-LSD is often described as “smoother” or more forgiving, while 1P-LSD may feel sharper or more mentally intense to some.

• Storage and stability
  The cyclopropionyl group in 1cP-LSD may offer marginally better stability over time, especially in powder form under ambient conditions.

• Legal classification differences
  Due to naming and structural distinctions, one may be legal while the other is banned in certain countries. Always confirm your local regulations.

• Availability in blotter and powder form
  Both are widely available in standard 100mcg blotters, but research-grade powder form is more common with 1cP-LSD.

• Interchangeable in research settings
  In most experimental protocols or self-directed research, both are used interchangeably due to their identical metabolic endpoint (LSD-25).